These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19601827)

  • 1. The role of exploratory drug metabolism and pharmacokinetics in new drug research: case study-selection of a thrombin receptor antagonist for development.
    Hsieh Y; Cheng KC; Wang Y; Chackalamannil S; Xia Y; Korfmacher WA; White RE
    Curr Pharm Des; 2009; 15(19):2262-9. PubMed ID: 19601827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput screening approaches for investigating drug metabolism and pharmacokinetics.
    Roberts SA
    Xenobiotica; 2001; 31(8-9):557-89. PubMed ID: 11569526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SCH 530348: a novel oral thrombin receptor antagonist.
    Bonaca MP; Morrow DA
    Future Cardiol; 2009 Sep; 5(5):435-42. PubMed ID: 19715408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection.
    Balani SK; Miwa GT; Gan LS; Wu JT; Lee FW
    Curr Top Med Chem; 2005; 5(11):1033-8. PubMed ID: 16181128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing DMPK Properties: Experiences from a Big Pharma DMPK Department.
    Sohlenius-Sternbeck AK; Janson J; Bylund J; Baranczewski P; Breitholtz-Emanuelsson A; Hu Y; Tsoi C; Lindgren A; Gissberg O; Bueters T; Briem S; Juric S; Johansson J; Bergh M; Hoogstraate J
    Curr Drug Metab; 2016; 17(3):253-70. PubMed ID: 26651977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New horizons in drug metabolism, pharmacokinetics and drug discovery.
    Palmer AM
    Drug News Perspect; 2003; 16(1):57-62. PubMed ID: 12682673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
    Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
    Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.
    Chackalamannil S; Wang Y; Greenlee WJ; Hu Z; Xia Y; Ahn HS; Boykow G; Hsieh Y; Palamanda J; Agans-Fantuzzi J; Kurowski S; Graziano M; Chintala M
    J Med Chem; 2008 Jun; 51(11):3061-4. PubMed ID: 18447380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
    Hildemann SK; Bode C
    Hamostaseologie; 2009 Nov; 29(4):349-55. PubMed ID: 19882073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirements for a lead compound to become a clinical candidate.
    Hefti FF
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S7. PubMed ID: 19091004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.
    Oestreich J
    Curr Opin Investig Drugs; 2009 Sep; 10(9):988-96. PubMed ID: 19705342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolite identification and profiling in drug design: current practice and future directions.
    Zhang Z; Zhu M; Tang W
    Curr Pharm Des; 2009; 15(19):2220-35. PubMed ID: 19601824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
    Masimirembwa CM; Bredberg U; Andersson TB
    Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Strategy of molecular drug design: hits, leads and drug candidates].
    Guo ZR
    Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-like property concepts in pharmaceutical design.
    Di L; Kerns EH; Carter GT
    Curr Pharm Des; 2009; 15(19):2184-94. PubMed ID: 19601822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the integration of drug metabolism into the lead optimization paradigm.
    Korfmacher WA
    Mini Rev Med Chem; 2009 Jun; 9(6):703-16. PubMed ID: 19519496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of oral drug absorption in humans--from cultured cell lines and experimental animals.
    Cheng KC; Li C; Uss AS
    Expert Opin Drug Metab Toxicol; 2008 May; 4(5):581-90. PubMed ID: 18484916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
    Beaumont K; Smith DA
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism.
    Baillie TA
    Chem Res Toxicol; 2008 Jan; 21(1):129-37. PubMed ID: 18052111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.